Lawrence D. Kaplan

MD

Director, Lymphoma Program
Hematologist-oncologist

About me

Dr. Lawrence D. Kaplan, a hematologist-oncologist, directs UCSF's lymphoma program. He is an international leader in the treatment of lymphoma and HIV-associated lymphoma.

In his research, Kaplan is particularly interested in developing new treatments for lymphoma and the HIV-related form of this cancer.

Kaplan earned his medical degree at the David Geffen School of Medicine at UCLA. He completed a residency in medicine at Boston Medical Center and completed a fellowship in hematology and oncology at UCSF. He joined UCSF in 1985.

Kaplan's professional activities include serving on the Lymphoma Working Group of the AIDS Malignancy Consortium, a clinical trials group supported by the National Cancer Institute (NCI). He formerly chaired the group's steering committee. He also serves on the lymphoma committee of Alliance for Clinical Trials in Oncology, a national research group sponsored by the NCI.

  • Education

    UCLA, 1980

  • Residencies

    Boston Medical Center, Medicine, 1983

  • Fellowships

    UCSF, Hematology and Oncology, 1985

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    French

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

My reviews

4.9

Overall Experience
167 Reviews
Dr. Kaplan is always caring and pays attention to my concerns. He never make me feel like a number but a patient he cares about.
Explained things in a way that was easy to understand
166 Reviews
Did the doctor pay attention to your concerns
165 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
157 Reviews
Knew the important information about your medical history
167 Reviews
The provider showed respect for what you had to say
167 Reviews
The provider spent enough time with me
167 Reviews
Decorative Caduceus

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving ...

Efficacy rates will be summarized by the proportion of participants who meet the criteria for efficacy, with 95% exact binomial CIs.

Recruiting

Decorative Caduceus

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorub...

There will be no formal statistical testing for the dose-finding portion of the study.

Recruiting

Share